Page last updated: 2024-09-05

melagatran and Liver Diseases

melagatran has been researched along with Liver Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Frison, L; Wåhlander, K	1

Trials

1 trial(s) available for melagatran and Liver Diseases

Article	Year
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics, 2003, Volume: 42, Issue:8 Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Glycine; Half-Life; Humans; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Prothrombin Time; Thrombin	2003

Article

Year

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Clinical pharmacokinetics, 2003, Volume: 42, Issue:8

Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Glycine; Half-Life; Humans; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Prothrombin Time; Thrombin

2003